David Johnson

GigaMune is developing novel technology for in vivo targeted gene delivery of T cell receptors (TCRs) and chimeric antigen receptors (CARs) to treat serious diseases such as cancer and autoimmune diseases. Our vision is to bring gene therapy into mainstream medicine through in vivo delivery of any gene to any cell in any tissue location. Our initial goal is to challenge conventional ex vivo cell therapy manufacturing by reducing costs and improving outcomes. See our high throughput immune screening technology highlighted in Nature Biotechnology (DOI: 10.1038/s41587-020-0438-y), and our petabase-scale protein search algorithm, published in Nature (DOI: 10.1038/s41586-021-04332-2).